US FDA to remove restrictions on Teva morning-after pill, but not generics
This article was originally published in SRA
Executive Summary
The US Department of Justice on 10 June advised a New York district judge that the Obama administration intends to drop its appeal against the court's April order requiring the Food and Drug Administration to make Teva's single-pill emergency contraceptive Plan B One-Step (1.5 mg levonorgestrel tablet), commonly called the morning after pill, available without a prescription and without point-of-sale or age restrictions1.
You may also be interested in...
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Clinton's Drug Price Plan: Threat Or Flash In The Political Pan?
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.